Driss Ait Ouakrim1, Seyedeh Ghazaleh Dashti1, Rowena Chau1, Daniel D Buchanan1, Mark Clendenning1, Christophe Rosty1, Ingrid M Winship1, Joanne P Young1, Graham G Giles1, Barbara Leggett1, Finlay A Macrae1, Dennis J Ahnen1, Graham Casey1, Steven Gallinger1, Robert W Haile1, Loïc Le Marchand1, Stephen N Thibodeau1, Noralane M Lindor1, Polly A Newcomb1, John D Potter1, John A Baron1, John L Hopper1, Mark A Jenkins1, Aung Ko Win1. 1. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia (DAO, SGD, RC, DDB, GGG, JLH, MAJ, AKW); Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia (DDB, MC, CR); University of Queensland, School of Medicine, Herston, Queensland, Australia (CR); Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia (IMW, FAM); Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Australia (IMW, FAM); Departments of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville, South Australia, Australia (JPY); SAHMRI Colorectal Node, Basil Hetzel Institute for Translational Research, Woodville, South Australia, Australia (JPY); School of Medicine, University of Adelaide, South Australia, Australia (JPY); Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia (GGG); QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Herston, Queensland, Australia (BL); Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Parkville, Victoria, Australia (FAM); Department of Medicine, University of Colorado School of Medicine, Denver, CO (DJA); Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA (GC); Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (SG); Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, CA (RWH); University of Hawaii Cancer Center, Honolulu, HI (LLM); Molecular Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN (SNT); Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, AZ (NML); Public Health Science
Abstract
BACKGROUND: Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 causes a high risk of colorectal and other cancers (Lynch Syndrome). Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers. The aim of this study was to determine whether use of aspirin and ibuprofen in a nontrial setting is associated with the risk of colorectal cancer risk for MMR gene mutation carriers. METHODS: We included 1858 participants in the Colon Cancer Family Registry who had been found to have a pathogenic germline mutation in a MMR gene (carriers). We used weighted Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS: A total of 714 carriers (38%) were diagnosed with colorectal cancer at a mean age of 42.4 (standard deviation 10.6) years. A reduced risk of colorectal cancer was associated with aspirin use (for 1 month to 4.9 years: HR = 0.49, 95% CI = 0.27 to 0.90, P = .02; for ≥5 years: HR = 0.25, 95% CI = 0.10 to 0.62, P = .003) and ibuprofen use (for 1 month to 4.9 years: HR = 0.38, 95% CI = 0.18 to 0.79, P = .009; for ≥5 years: HR = 0.26, 95% CI = 0.10 to 0.69, P = .007), compared with less than one month of use. CONCLUSION: Our results provide additional evidence that, for MMR gene mutation carriers, use of aspirin and ibuprofen might be effective in reducing their high risk of colorectal cancer.
BACKGROUND: Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 causes a high risk of colorectal and other cancers (Lynch Syndrome). Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers. The aim of this study was to determine whether use of aspirin and ibuprofen in a nontrial setting is associated with the risk of colorectal cancer risk for MMR gene mutation carriers. METHODS: We included 1858 participants in the Colon Cancer Family Registry who had been found to have a pathogenic germline mutation in a MMR gene (carriers). We used weighted Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS: A total of 714 carriers (38%) were diagnosed with colorectal cancer at a mean age of 42.4 (standard deviation 10.6) years. A reduced risk of colorectal cancer was associated with aspirin use (for 1 month to 4.9 years: HR = 0.49, 95% CI = 0.27 to 0.90, P = .02; for ≥5 years: HR = 0.25, 95% CI = 0.10 to 0.62, P = .003) and ibuprofen use (for 1 month to 4.9 years: HR = 0.38, 95% CI = 0.18 to 0.79, P = .009; for ≥5 years: HR = 0.26, 95% CI = 0.10 to 0.69, P = .007), compared with less than one month of use. CONCLUSION: Our results provide additional evidence that, for MMR gene mutation carriers, use of aspirin and ibuprofen might be effective in reducing their high risk of colorectal cancer.
Authors: Melissa C Southey; Mark A Jenkins; Leeanne Mead; Jonathan Whitty; Melanie Trivett; Andrea A Tesoriero; Letitia D Smith; Kim Jennings; Garry Grubb; Simon G Royce; Michael D Walsh; Melissa A Barker; Joanne P Young; Jeremy R Jass; D James B St John; Finlay A Macrae; Graham G Giles; John L Hopper Journal: J Clin Oncol Date: 2005-08-22 Impact factor: 44.544
Authors: Antonis C Antoniou; David E Goldgar; Nadine Andrieu; Jenny Chang-Claude; Richard Brohet; Matti A Rookus; Douglas F Easton Journal: Genet Epidemiol Date: 2005-07 Impact factor: 2.135
Authors: Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11-02 Impact factor: 4.254
Authors: Antonis C Antoniou; Amanda B Spurdle; Olga M Sinilnikova; Sue Healey; Karen A Pooley; Rita K Schmutzler; Beatrix Versmold; Christoph Engel; Alfons Meindl; Norbert Arnold; Wera Hofmann; Christian Sutter; Dieter Niederacher; Helmut Deissler; Trinidad Caldes; Kati Kämpjärvi; Heli Nevanlinna; Jacques Simard; Jonathan Beesley; Xiaoqing Chen; Susan L Neuhausen; Timothy R Rebbeck; Theresa Wagner; Henry T Lynch; Claudine Isaacs; Jeffrey Weitzel; Patricia A Ganz; Mary B Daly; Gail Tomlinson; Olufunmilayo I Olopade; Joanne L Blum; Fergus J Couch; Paolo Peterlongo; Siranoush Manoukian; Monica Barile; Paolo Radice; Csilla I Szabo; Lutecia H Mateus Pereira; Mark H Greene; Gad Rennert; Flavio Lejbkowicz; Ofra Barnett-Griness; Irene L Andrulis; Hilmi Ozcelik; Anne-Marie Gerdes; Maria A Caligo; Yael Laitman; Bella Kaufman; Roni Milgrom; Eitan Friedman; Susan M Domchek; Katherine L Nathanson; Ana Osorio; Gemma Llort; Roger L Milne; Javier Benítez; Ute Hamann; Frans B L Hogervorst; Peggy Manders; Marjolijn J L Ligtenberg; Ans M W van den Ouweland; Susan Peock; Margaret Cook; Radka Platte; D Gareth Evans; Rosalind Eeles; Gabriella Pichert; Carol Chu; Diana Eccles; Rosemarie Davidson; Fiona Douglas; Andrew K Godwin; Laure Barjhoux; Sylvie Mazoyer; Hagay Sobol; Violaine Bourdon; François Eisinger; Agnès Chompret; Corinne Capoulade; Brigitte Bressac-de Paillerets; Gilbert M Lenoir; Marion Gauthier-Villars; Claude Houdayer; Dominique Stoppa-Lyonnet; Georgia Chenevix-Trench; Douglas F Easton Journal: Am J Hum Genet Date: 2008-03-20 Impact factor: 11.025
Authors: Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Eva S Schernhammer; Kana Wu; Charles S Fuchs Journal: Gastroenterology Date: 2007-09-26 Impact factor: 22.682
Authors: Leigha Senter; Mark Clendenning; Kaisa Sotamaa; Heather Hampel; Jane Green; John D Potter; Annika Lindblom; Kristina Lagerstedt; Stephen N Thibodeau; Noralane M Lindor; Joanne Young; Ingrid Winship; James G Dowty; Darren M White; John L Hopper; Laura Baglietto; Mark A Jenkins; Albert de la Chapelle Journal: Gastroenterology Date: 2008-05-02 Impact factor: 22.682
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Robert A Smith; Durado Brooks; Kimberly S Andrews; Chiranjeev Dash; Francis M Giardiello; Seth Glick; Theodore R Levin; Perry Pickhardt; Douglas K Rex; Alan Thorson; Sidney J Winawer Journal: CA Cancer J Clin Date: 2008-03-05 Impact factor: 508.702
Authors: Xinwei Hua; Amanda I Phipps; Andrea N Burnett-Hartman; Scott V Adams; Sheetal Hardikar; Stacey A Cohen; Jonathan M Kocarnik; Dennis J Ahnen; Noralane M Lindor; John A Baron; Polly A Newcomb Journal: J Clin Oncol Date: 2017-06-15 Impact factor: 44.544
Authors: Mark A Jenkins; Aung Ko Win; Allyson S Templeton; Maggie S Angelakos; Daniel D Buchanan; Michelle Cotterchio; Jane C Figueiredo; Stephen N Thibodeau; John A Baron; John D Potter; John L Hopper; Graham Casey; Steven Gallinger; Loic Le Marchand; Noralane M Lindor; Polly A Newcomb; Robert W Haile Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196
Authors: Fay Kastrinos; Hajime Uno; Chinedu Ukaegbu; Carmelita Alvero; Ashley McFarland; Matthew B Yurgelun; Matthew H Kulke; Deborah Schrag; Jeffrey A Meyerhardt; Charles S Fuchs; Robert J Mayer; Kimmie Ng; Ewout W Steyerberg; Sapna Syngal Journal: J Clin Oncol Date: 2017-05-10 Impact factor: 44.544
Authors: Rowena Chau; Seyedeh Ghazaleh Dashti; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Finlay A Macrae; Alex Boussioutas; Susan Parry; Jane C Figueiredo; A Joan Levine; Dennis J Ahnen; Graham Casey; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win Journal: Int J Epidemiol Date: 2016-04-10 Impact factor: 7.196